Compare LAUR & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAUR | CRSP |
|---|---|---|
| Founded | 1989 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.9B |
| IPO Year | 2015 | 2016 |
| Metric | LAUR | CRSP |
|---|---|---|
| Price | $33.68 | $57.26 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 17 |
| Target Price | $39.63 | ★ $70.29 |
| AVG Volume (30 Days) | 974.5K | ★ 1.5M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,484,288,000.00 | $289,590,000.00 |
| Revenue This Year | $14.58 | $807.72 |
| Revenue Next Year | $7.85 | $172.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 19.48 | ★ 9169.85 |
| 52 Week Low | $21.16 | $39.81 |
| 52 Week High | $37.91 | $78.48 |
| Indicator | LAUR | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 57.17 | 60.77 |
| Support Level | $33.10 | $50.72 |
| Resistance Level | $34.46 | $60.29 |
| Average True Range (ATR) | 0.98 | 2.51 |
| MACD | 0.10 | 0.49 |
| Stochastic Oscillator | 73.14 | 84.77 |
Laureate Education Inc is an international community of universities. The company provides higher education programs and services to students through an international network of licensed universities and higher education institutions. Its reportable segments include Peru and Mexico, of which Mexico derives maximum revenue. Geographically, the company operates in Mexico, Peru and United States.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.